Treatment of Immune-Mediated Glomerulonephritis
Treatment of immune-mediated glomerulonephritis requires a three-pronged approach: (1) immediate control of disease activity with immunosuppression tailored to disease severity and type, (2) prevention of progression through proteinuria reduction, and (3) minimization of treatment-related toxicity through infection prophylaxis and monitoring 1.
Core Treatment Principles
The KDIGO 2021 guidelines establish that treatment intensity must match disease severity and specific glomerulonephritis type 1. Your immunosuppression regimen must simultaneously:
- Avert immediate morbidity from the primary disease process
- Prevent disease progression (recognizing complete remission may not be achievable in all chronic forms)
- Minimize harmful immunosuppression side effects through shared decision-making and prophylaxis
Specific Treatment Algorithms by Disease Type
For Membranous Nephropathy with Risk Factors for Progression:
Use rituximab OR cyclophosphamide with alternate-month glucocorticoids for 6 months OR tacrolimus-based therapy for 6 months, with choice depending on individual risk stratification 1. Rituximab is preferred over cyclophosphamide by most physicians and patients due to superior safety profile 1.
For Lupus Nephritis:
- Active disease: Use immunosuppression regimens similar across adults and children, with glucocorticoids, hydroxychloroquine, azathioprine, tacrolimus, or cyclosporine as safe options 2
- During pregnancy: Continue hydroxychloroquine and add low-dose aspirin before 16 weeks gestation 2
- Avoid pregnancy during active disease or teratogenic drug treatment, and for ≥6 months after disease becomes inactive 2
For IgA Nephropathy (proteinuria ≥0.5 g/day):
Combine behavioral modifications (sodium <2 g/day, smoking cessation, weight control) with blood pressure control (<120/70 mmHg) and therapies including targeted-release budesonide, systemic glucocorticoids, iptacopan, renin-angiotensin system inhibitors, dual endothelin-angiotensin receptor antagonists (sparsentan), and SGLT2 inhibitors 3.
Universal Supportive Measures
Blood Pressure and Proteinuria Management:
- Target BP <120/70 mmHg using renin-angiotensin system blockade
- Dietary sodium restriction <2.0 g/day (<90 mmol/day) 1
- Protein restriction based on proteinuria degree 1
- Aim for ≥40% decline in proteinuria as surrogate endpoint 1
Mandatory Infection Prevention:
Before starting immunosuppression, screen for tuberculosis, hepatitis B/C, HIV, and syphilis 1. Consider Strongyloides in patients from endemic tropical areas with eosinophilia 1.
Prophylactic trimethoprim-sulfamethoxazole is required for patients receiving high-dose prednisone, rituximab, or cyclophosphamide 1.
Required Vaccinations:
- Pneumococcal vaccine for all patients with glomerular disease and nephrotic syndrome 1
- Annual influenza vaccine for patients and household contacts 1
- Herpes zoster vaccination (Shingrix) 1
Dose Adjustments and Monitoring
Adjust immunosuppression dosing based on GFR level to ensure safety 1. Monitor therapeutic drug levels where clinically indicated and screen for development of cancers or infections during prolonged immunosuppression 1.
Common Pitfalls to Avoid
Do not delay treatment in rapidly progressive glomerulonephritis—induction therapy intensity must match presenting symptom severity 1.
Do not assume clinical findings correlate with histologic severity—kidney biopsy remains essential for diagnosis confirmation and treatment planning, particularly in lupus nephritis where clinical parameters can be misleading 2.
Do not forget fertility preservation counseling before initiating potentially gonadotoxic agents like cyclophosphamide 1.
Recognize that multiple rounds of immunosuppression increase cumulative toxic drug exposure over time, requiring ongoing risk-benefit reassessment 1.